ArticleThe American journal of gastroenterology2020
Predicting Progression in Barrett's Esophagus: Is the Holy Grail Within Reach?
Article in The American journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systematic Review and Meta-Analysis of TissueCypher and p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus.Gastro hep advances · 2026Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Risk stratification in Barrett's esophagus may allow aggressive management of those at "high risk" and reduction in surveillance in at "low" risk. Davison et al. report the results of the independent validation of a multibiomarker panel (TissueCypher assay) performed on biopsy tissue, in a case control study. "High-risk" patients progressed 5 times more than those at "low risk." Sensitivity and specificity for "high-risk" patients were 29% and 86% with a positive predictive value of 23%. A negative predictive value of a "low-risk" score was 96%. These findings may allow more intensive surveillance in those at "high risk." Despite some limitations, this assay is a potentially major advance in the management of Barrett's esophagus patients without dysplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.